2′-C-β-Methylguanosine
(Synonyms: 2'-C-甲基鸟苷) 目录号 : GC49823An active nucleoside metabolite of BMS-986094
Cas No.:374750-30-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2’-C-β-Methylguanosine is an active nucleoside metabolite of the antiviral prodrug BMS-986094.1 It inhibits replication in genotype 1b hepatitis C virus (HCV) replicon cells (EC50s = 5.2 and 3.2 µM in ELISA and luciferase assays, respectively).2 2’-C-β-Methylguanosine also inhibits replication of the Zika virus clinical isolate ZIKVPE243 in infected human brain microvascular endothelial cells (HBMECs), SH-SY5Y cells, and Vero cells (EC50s = 0.88, 2.09, and 1.25 µM, respectively) but is toxic to mice infected with ZIKVPE243 at postnatal day 2 when administered at a dose of 25 mg/kg per day.3
1.Liu, A., Lute, J., Gu, H., et al.Challenges and solutions in the bioanalysis of BMS-986094 and its metabolites including a highly polar, active nucleoside triphosphate in plasma and tissues using LC-MS/MSJ. Chromatogr. B Analyt. Technol. Biomed. Life Sci.100029-40(2015) 2.Sizun, G., Pierra, C., Peyronnet, J., et al.Design, synthesis and antiviral evaluation of 2’-C-methyl branched guanosine pronucleotides: The discovery of IDX184, a potent liver-targeted HCV polymerase inhibitorFuture Med. Chem.7(13)1675-1700(2015) 3.Matos de Souza, M.R., Cunha, M.S., Okon, A., et al.In vitro and in vivo characterization of the anti-Zika virus activity of ProTides of 2’-C-β-methylguanosineACS Infect. Dis.6(7)1650-1658(2020)
Cas No. | 374750-30-8 | SDF | Download SDF |
别名 | 2'-C-甲基鸟苷 | ||
Canonical SMILES | C[C@@]1([C@](O[C@@H]([C@H]1O)CO)([H])N2C3=C(C(N=C(N3)N)=O)N=C2)O | ||
分子式 | C11H15N5O5 | 分子量 | 297.3 |
溶解度 | DMF: 2 mg/ml,DMSO: 1 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3636 mL | 16.818 mL | 33.6361 mL |
5 mM | 0.6727 mL | 3.3636 mL | 6.7272 mL |
10 mM | 0.3364 mL | 1.6818 mL | 3.3636 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。